Market is really waiting for FebriDx big healthcare provider agreements, which in all likelihood are a while off.
If you watch the webinar you will see that there are a few steps still in order to gain CLIA waiver. Not sure the timeline, but wouldn't expect it anytime soon.
Lumos did ship first sales of FebriDx in late December as promised, but the big agreements as everyone expected by end of last year can't come till CLIA waiver is granted.
According to the webinar around 95% of Lumos business is exactly the type of work they are doing with the new contract. FebriDx will have its time, and could well likely catapult Lumos if it gains traction, but even so, the diagnostics and poc reader part of the business has the potential to be many multiples of the current contract in the future, with continued revenue year after year.
LDX Price at posting:
7.8¢ Sentiment: Buy Disclosure: Held
